samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Clinerion’s revolutionary ANID technology for de-identification and identification of patient record data in Patient Network Explorer is now patent protected

Clinerion



Basel, Switzerland, 5th May, 2022 - Highlights:

  • ANID is based on fully de-identified patient records, with no use of pseudo-IDs
  • Newly patented technology uses a combination of techniques to match de-identified records with corresponding hospital medical records
  • Newly patented system set-up increases data security and privacy protection
  • The newly patented technology uses de-identified records, but enables the duly authorized clinical trial manager at the hospital to identify eligible clinical trial candidate patients
  • Technology has been in use in the Patient Network Explorer hospital network since 2017

The newly patented ANID technology, implemented in the hospitals in Clinerion’s global hospital network on Patient Network Explorer since 2017, significantly increases the security of private information when using patient medical records to evaluate study feasibility, or identifying patients for enrollment in clinical trials.

The ANID technology exclusively uses fully de-identified records, wherein all identifiable personal information and patient record identifiers have been completely stripped from medical records before use, with no use of pseudo-IDs (pseudonymization). The duly authorized clinical trial manager at the hospital may however still identify eligible patients.

In contrast to a pseudonymization process, which relies on storing identifying information in two separate locations (pseudo-ID and lookup table) and enables identification when the two pieces of the puzzle are combined, ANID technology involves three pieces (de-identified record, structure calculation and lookup table). This provides the fundamental advantage of using fully de-identified data which yet allows patient identification.

While offering a new, enhanced level of data protection, ANID maintains all the advantages of the existing Clinerion technology, such as following HIPAA rules regarding protection against accidental identification. Query results for feasibility requests are stored in the Clinerion secure private cloud environment, which only sees aggregated counts of the patients which fit the queries. The performance of the Clinerion Patient Network Explorer is not affected, results still appear in real-time and trial recruitment remains more efficient and effective than through conventional methods.

“Patient data security by design is one of the core principles of the whole Patient Network Explorer pipeline,” says Dr. Andreas Walter, Clinerion Chief Technology Officer. “We are proud of having received the ANID patent in addition to another patent for the Patient Network Explorer infrastructure received in 2021.”

“Clinerion has always been very clear that patients are at the center of everything that we do,” says Dr. Barış Erdoğan, Clinerion Chief Executive Officer. “By extension, protection of patient data is also at the forefront of our concerns. This is why we came up with the idea of ANID: to ensure patient privacy.”

The patent EP 2017/069859, “PATIENT RECRUITMENT SYSTEM,” was published in the European Patent Bulletin 2022/16 on April 20th, 2022. The patent was submitted on August 4th, 2017. The related US patent is expected to be published soon.
phone +41 61 865 60 60
email info@clinerion.com
web www.clinerion.com/
email Elisabethenanlage 11, 4051 Basel, Switzerland
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Pioneering a New Era of Cell Therapy Manufacturing

Aug 09 2022: Following its successful inspection, our Memphis cell therapy manufacturing facility is paving the way in the cell and gene therapy industry as the first contract development and manufacturing organization (CDMO) in North America to be awarded a commercial GMP license to produce allogeneic cell therapy drug products from the European Medicines Agency (EMA).
More info >>


White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

Industry Events

Connect in Pharma

14-15 September 2022, Plaexpo, Geneva, Switzerland

The new event driving innovation for pharma and biopharma businesses, Connect in Pharma will unite key players in Pharmaceutical and Biopharmaceutical packaging and production in Geneva on 14 – 15 September 2022.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement